Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Pralsetinib Approved in Europe for RET Fusion+ Advanced NSCLC

November 19th 2021

The European Commission has granted a conditional marketing authorization to pralsetinib for use as a single agent in adult patient with RET fusion–positive advanced non–small cell lung cancer who did not previously receive a RET inhibitor.

Future Outlook

November 19th 2021

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, reflect on treatments being developed in the non-small cell lung cancer space that they are excited for and provide some key takeaways and advice for colleagues.

Treating ALK-Mutant and KRAS G12C–Mutant NSCLC

November 19th 2021

Lung cancer experts share updates in the treatment of ALK-mutant NSCLC and KRAS G12C–mutant NSCLC as seen in the CROWN study, BrigALK2 real-world study, and CODEBreaK 100 study.

Treatment of MET Exon 14 Mutations in NSCLC

November 19th 2021

Heather Wakelee, MD, reviews key data for the treatment of MET exon 14 mutations in NSCLC as seen in the GeoMETry-III trial and the CRYSALIS study.

Other Agents Targeting EGFR Exon 20 Insertion Mutations in NSCLC

November 18th 2021

Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.

Key Differences Between Amivantamab and Mobocertinib in NSCLC

November 18th 2021

Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Experts Chip Away at Resistance, Sequencing, and Targeted Therapy Selection in Lung Cancer

November 17th 2021

Edgardo Santos, MD, discusses the current state of targeted therapies for EGFR- and ALK-positive non–small cell lung cancer, as well as immunotherapy in stage III NSCLC, and management strategies in small cell lung cancer.

Dr. Langer on the Evolution of Molecular Testing in Advanced NSCLC

November 15th 2021

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.

Dr. Le on the Emergence of Antibody-Drug Conjugates in NSCLC

November 15th 2021

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Dr. Patel Discusses Novel Targets in NSCLC

November 15th 2021

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC

November 15th 2021

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

Sotorasib Approaches EU Approval for KRAS G12C–Mutated Advanced NSCLC

November 12th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of sotorasib for the treatment of adult patients with advanced non–small cell lung cancer whose tumors harbor a KRAS G12C mutation and who have progressed after at least 1 prior line of systemic therapy.

Treating EGFR Exon 20 Insertions and HER2-Mutant NSCLC

November 12th 2021

Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.

Treatment of TKI-Refractory EGFR-Mutant NSCLC

November 12th 2021

Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.

Dr. Ivanick on the Diagnostic Role of Interventional Pulmonologists in Lung Cancer

November 11th 2021

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Additional Studies with Antibody-Drug Conjugates in NSCLC

November 11th 2021

Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.

Trilaciclib Possesses Potential to Reduce Burden of Chemotherapy-Induced Myelosuppression in ES-SCLC

November 11th 2021

The administration of trilaciclib prior to chemotherapy reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with extensive-stage small cell lung cancer.

NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.